Larger group testing

The next step is to carry out longer testing of the treatment in much larger groups of people (sometimes thousands) with the specific condition, compared against an existing treatment or a placebo to see which works better, while still checking side effects.

 

Interstitial lung diseases

 

  • Zephyrus II: A phase 3, randomized, double-blind, placebo-controlled efficacy and safety study of Pamrevlumab in subjects with Idiopathic Pulmonary Fibrosis:
    • The purpose of this study is to test whether Pamrevlumab will slow down the progression of your lung disease, IPF.  Pamrevlumab works by interfering with neutralising Connective Tissue Growth Factor (CTGF), a protein that the body normally produces. Studies have shown increased activity/levels of CTGF in IPF patients, which might be an important factor in the disease progression.

Breathing Matters Impact Report 2021

See how your donations have contributed to our groundbreaking research

2021 Impact Report

Sign Up!

Receive our latest research updates and news

  • This form collects your name and email address so that we can keep you updated with news and information about Breathing Matters. Please check our Privacy Policy to see how we protect and manage your data.

Sign up to receive our news and updates

  • This form collects your name and email address so that we can keep you updated with news and information about Breathing Matters. Please check our Privacy Policy to see how we protect and manage your data.

Where there's research there's hope

Research into respiratory conditions accounts for just 2% of all the medical research funding in the UK.

Will you support respiratory research?